Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Acts as a transcriptional coactivator for NOTCH proteins. Additionally we are shipping and many more products for this protein.
Showing 10 out of 42 products:
Human Polyclonal MAML2 Primary Antibody for IP, WB - ABIN151565
Oyama, Harigaya, Sasaki, Okamura, Kokubo, Saga, Hozumi, Suganami, Tamura, Nagase, Koga, Nishimura, Sakamoto, Sato, Yoshida, Kitagawa: Mastermind-like 1 (MamL1) and mastermind-like 3 (MamL3) are essential for Notch signaling in vivo. in Development (Cambridge, England) 2011
Detection of the CRTC1 (show CRTC1 Antibodies)/MAML2 fusion transcript provides useful information for MEC (show CCL28 Antibodies) diagnosis but is not associated with differences in survival outcomes.
The molecular basis underlying CRTC1 (show CRTC1 Antibodies)-MAML2 oncogenic functions were identified in mucoepidermoid carcinoma cells.
SNPs in Notch (show NOTCH1 Antibodies) pathway genes may be predictors of cutaneous melanoma disease-specific survival.
We identified MAML2 rearrangements in five of nine odontogenic cysts lined by mucus-secreting cells
Translocation t(11;19)(q14-21;p12-13) in patients with Salivary mucoepidermoid carcinoma was reported , which results in fusion between exons 1 and 2 of MAML2 on chromosome 11q21.Fusion positive, MAML2 re-arrangements are present in 50-70 % of MECs.
The high sensitivity and specificity of MAML2 rearrangement for central mucoepidermoid carcinoma points to its utility as a diagnostic adjunct in separating mucinous cystic lesions of the gnathic bones.
MAML2 rearrangement appears frequent in PMEC and specific with this tumor. Both the presence of MAML2 rearrangement and absence of FLT1 (show FLT1 Antibodies) tend to confer a favorable clinical outcome.
Malignant mucoepidermoid salivary gland tumors can arise from a recurrent t (11, 19)(q21;p13.1) translocation that generates an unusual chimeric CRTC1 (show CRTC1 Antibodies)/MAML2 oncoprotein.
The rearrangement between MAML2 and CXCR4 (show CXCR4 Antibodies), created by a t(2;11)(q22.1;q21) translocation, results in a new fusion gene in which a portion of CXCR4 (show CXCR4 Antibodies) is linked to the MAML2 gene.
aberrantly activated AREG (show AREG Antibodies)-EGFR (show EGFR Antibodies) signaling is required for CRTC1 (show CRTC1 Antibodies)-MAML2-positive MEC (show CCL28 Antibodies) cell growth and survival, suggesting that EGFR (show EGFR Antibodies)-targeted therapies will benefit patients with advanced, unresectable CRTC1 (show CRTC1 Antibodies)-MAML2-positive MEC (show CCL28 Antibodies).
Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Potentiates activation by NOTCH3 and NOTCH4 more efficiently than MAML1 or MAML3 (By similarity).
mastermind like 2
, mastermind-like 2
, mastermind-like protein 2